Switch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up
journal contribution
posted on 2012-05-20, 00:00 authored by J Lipton, T Hughes, B Leber, C De Souza, P Dorlhiac-Llacer, J Steegmann, A Guerci-Bresler, A Schwarer, F Cervantes, John Reynolds, L Collins, T Szczudlo, N SpectorSwitch to nilotinib versus continued imatinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) with detectable BCR-ABL after 2 or more years on imatinib : ENESTcmr 12-month (mo) follow-up
History
Journal
Journal of clinical oncologyVolume
30Issue
15Season
May 20 Supplement; Abstract No. : 6505Pagination
1 - 1Publisher
American Society of Clinical OncologyLocation
Alexandria, Va.ISSN
0732-183XeISSN
1527-7755Language
engNotes
Alternative source title : Journal of clinical oncology, 2012 ASCO annual meeting abstracts; Oral presentation at American Society of Clinical Oncology Annual Meeting (48th : 2012 : Chicago, Illinois) held from 1 - 5 Jun. 2012Publication classification
C2.1 Other contribution to refereed journalUsage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC